High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder

Psychopharmacology

Volumn 233, Issue 1, 2016, Pages 49-56

  Salvi, Virginio ^a   Barone Adesi, Francesco ^b   D'Ambrosio, Virginia ^a   Albert, Umberto ^a   Maina, Giuseppe ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Affinity; Antidepressant; Cardiovascular; Histamine; Metabolism

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ARTICLE; BINDING AFFINITY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; WEIGHT GAIN;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RECEPTORS, HISTAMINE H1; RISK FACTORS; WEIGHT GAIN;

EID: 84952932054     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4085-9     Document Type: Article

References (38)

1. American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder, revision. Am J Psychiatry 159:1-50
2. Barnard K, Peveler RC, Holt RI (2013) Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 36:3337-3345
3. Bly MJ, Taylor SF, Dalack G et al (2014) Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord 16:277-288
4. Bradford DW, Kim MM, Braxton LE, Marx CE, Butterfield M, Elbogen EB (2008) Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv 59:847-852
5. Cardenas J, Frye MA, Marusak SL et al (2008) Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 106(1-2):91-97
6. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Ongur D (2012) Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 27:521-526
7. Cerit C, Vural M, Bos Gelmez SÜ, Ozten E, Aker AT, Yildiz M (2010) Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull 43:22-36
8. Derijks HJ, Heerdink ER, Janknegt R, De Koning FH, Janknegt R, Lindquist M, Egberts AC (2008a) The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 64:531-538
9. Derijks HJ, Heerdink ER, Janknegt R, De Koning FH, Olivier B, Loonen AJM, Egberts AC (2008b) Visualizing pharmacological activities of antidepressants: a novel approach. Open J Pharmacol 2:54-62
10. Diacinti D, Pisani D, Barone-Adesi F, Del Fiacco R, Minisola S, David V, Aliberti G, Mazzuoli GF (2010) A new predictive index for vertebral fractures: the sum of the anterior vertebral body heights. Bone 46(3):768-773
11. Fagiolini A, Chengappa KN, Soreca I, Chang J (2008) Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 22:655-669
12. Garcia-Portilla MP, Saiz PA, Benabarre A, Florez G, Bascaran MT, Diaz EM, Bousoño M, Bobes J (2010) Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scand 121:437-445
13. Godin O, Etain B, Henry C et al (2014) FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry 75(10):1078-1085
14. Grundy SM, Cleeman JI, Daniels SR, American Heart Association, National Heart, Lung and Blood Institute et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752
15. Grundy A, Cotterchio M, Kirsh VA, Kreiger N (2014) Associations between anxiety, depression, antidepressant medication, obesity and weight gain among Canadian women. PLoS ONE 9(6), e99780
16. Haeberle A, Greil W, Russmann S, Grohmann R (2012) Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 12:153
17. He M, Deng C, Huang XF (2013) The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 27:423-434
18. Jørgensen EA, Knigge U, Warberg J, Kjaer A (2007) Histamine and the regulation of body weight. Neuroendocrinology 86(3):210-4
19. Kroeze WK, Hufeisen SJ, Popadak BA et al (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
20. Maina G, Albert U, Salvi V, Bogetto F (2004) Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 65:1365-1371
21. McIntyre R, Soczynska JK, Konarski JZ (2006) The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 5:523-537
22. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG (2009) Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr Psychiatry Rep 11:475-480
23. Ostacher MJ (2006) The evidence for antidepressant use in bipolar depression. J Clin Psychiatry 67(Suppl 11):18-21
24. Pacchiarotti I, Bond DJ, Baldessarini RJ et al (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170:1249-1262
25. Petersen MR, Deddens JA (2008) A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol 28:8-9
26. Salvi V, D'Ambrosio V, Bogetto F, Maina G (2012) Metabolic syndrome in Italian patients with bipolar disorder: a 2-year follow-up study. J Affect Disord 136(3):599-603
27. Schilling C, Gilles M, Blum WF et al (2013) Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? J Clin Psychopharmacol 33:99-103
28. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ (2015) The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. doi: 10.1111/acps.12439
29. Sussman M, Friedman M, Korn JR, Hassan M, Kim J, Menzin J (2012) The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes: findings from a managed care setting. J Affect Disord 138:425-432
30. Thompson ML, Myers JE, Kriebel D (1998) Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med 55(4):272-277
31. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, Probst M, De Hert M (2013) Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 170:265-274
32. Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B (2015a) Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry 2015 Jul 7.
33. Vancampfort D, Sienaert P, Wyckaert S, De Hert M, Stubbs B, Soundy A, De Smet J, Probst M (2015b) Health-related physical fitness in patients with bipolar disorder vs. healthy controls: an exploratory study. J Affect Disord 177:22-7
34. Wu CS, Gau SS, Lai MS (2014) Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan. J Clin Psychiatry 75:31-38
35. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, Oral ET, Atagun T (2006) Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 98(3):247-252
36. Zarate CA Jr, Quiroz JA (2003) Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 5:217-225
37. Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl SM (2014) A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 24:1005-1014
38. Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702-706